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Abstract
The c-Myc transcription factor regulates expression of
genes related to cell growth, division, and apoptosis.
Mxi1, a member of the Mad family, represses tran-
scription of c-Myc–regulated genes by mediating
chromatin condensation via histone deacetylase and
the Sin3 corepressor. Mxi1 is a c-Myc antagonist and
suppresses cell proliferation in vitro. Here, we describe
the identification of MXI1-0, a novel Mxi1 isoform that
is alternatively transcribed from an upstream exon.
MXI1-0 and Mxi1 have different amino-terminal se-
quences, but share identical Max- and DNA-binding
domains. Both isoforms are able to bind Max, to rec-
ognize E-box binding sites, and to interact with Sin3.
Despite these similarities and in contrast to Mxi1,MXI1-
0 is predominantly localized to the cytoplasm and fails
to repress c-Myc–dependent transcription. Although
MXI1-0 and Mxi1 are coexpressed in both human and
mouse cells, the relative levels of MXI1-0 are higher
in primary glioblastoma tumors than in normal brain
tissue. This variation in the levels of MXI1-0 and Mxi1
suggests that MXI1-0 may modulate the Myc-inhibitory
activity of Mxi1. The identification of MXI1-0 as an
alternatively transcribed Mxi1 isoform has significant
implications for the interpretation of previous Mxi1
studies, particularly those related to the phenotype of
the mxi1 knockout mouse.
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Introduction
The Myc family of transcription factors has been implicated
in the pathogenesis of a variety of cancers. Myc contributes
to enhanced proliferation and tumorigenesis by multiple
mechanisms, and recent studies have indicated a key role
for Myc-dependent transcriptional activation and repres-
sion of genes necessary for proliferation and survival
[1–4]. The identification of the Mad family of Myc antag-
onists (Mad1, Mxi1, Mad3, Mad4, Rox/Mnt, Mga) led to
the recognition that the regulation of genes by Myc is
complex [5–10]. Numerous studies have demonstrated
the ability of Mad proteins to counteract the ability of Myc
to transform cells, as well as to reduce Myc-dependent
transactivation (reviewed in Refs. [11–14]). Whereas Mad
proteins recruit histone deacetylase to actively repress tran-
scription, the precise means by which Mad proteins regulate
Myc activity, as well as their role in the normal differentiation
process, remain unclear. The specific features that distin-
guish the function of individual Mad family members from
each other are also unknown.
Mxi1 was initially identified as a heterodimeric partner for
Max using the yeast-two hybrid system [6]. The human MXI1
gene is located on chromosome 10q24–q25 [15,16] and is
composed of six exons (roughly corresponding to Mxi1 func-
tional domains) that span >60 kb [17]. The ability of Mxi1 to
interact with the Sin3 corepressor results in recruitment of
histone deacetylase to the promoters of regulated genes, with
consequent chromatin condensation and transcriptional re-
pression [18–22]. Numerous studies have demonstrated the
ability of Mxi1 to counteract Myc-dependent transcription and
transformation, and overexpression of Mxi1 results in growth
arrest [6,23–25]. The possibility that MXI1 is a tumor suppres-
sor gene (by virtue of its antagonism of Myc) is supported by
the tumor-prone phenotype of the mxi1 knockout mouse [26].
However, only a small fraction of prostate and neurofibrosar-
coma tumors have been shown to harbor MXI1 coding se-
quence mutations [27–29]. A recent study indicates that Mxi1
may regulate a set of genes distinct from those regulated by
Myc [30]. The precise mechanisms by which Mxi1 produces its
repressive effects and the interplay among the various Mad
family members remain to be clarified.
After the discovery of human MXI1 [6], several groups
independently identified mxi1 homologues in the mouse.
Shapiro et al. [15] first mapped the mouse mxi1 locus to chro-
mosome 19, a region syntenic with human chromosome 10q.
Subsequently, Schreiber-Agus et al. [19] described a mouse
Mxi1 isoform (hereafter referred to as mMxi1) whose amino
acid sequence was essentially identical to humanMxi1 (hMxi1),
except for minor C-terminal residue differences (Figure 1A).
Abbreviations: RT-PCR, reverse transcription– polymerase chain reaction; IP, immunopreci-
pitation; WCL, whole cell lysate; HA, hemagglutinin; SID, Sin3 interaction domain
Address all correspondence to: Daniel S. Wechsler, Section of Pediatric Hematology-
Oncology, The University of Michigan, 1500 East Medical Center Drive, CCGC 4312, Ann
Arbor, MI 48109-0936. E-mail: dwechsl@umich.edu
Received 19 March 2004; Revised 14 June 2004.
Copyright D 2004 Neoplasia Press, Inc. All rights reserved 1522-8002/04/$25.00
DOI 10.1593/neo.04244
Neoplasia . Vol. 6, No. 5, September/October 2004, pp. 660–673 660
www.neoplasia.com
RESEARCH ARTICLE
Figure 1. (A) Identification of different human (h) and mouse (m) Mxi1 isoforms. Bars represent sequences encoded by exons 2 to 6 in human (hatched) and mouse
(shaded) isoforms. Vertical bars in the mMxi1 forms indicate single amino acid (aa) differences from hMxi1. Solid black bars are derived from exon 1 sequence and
open white bars from exon 0 sequence. Start codons (ATG) and aa numbers are shown above and below bars, respectively. Start codons corresponding to the strong
(SR) and weak repressor (WR) isoforms of mouse Mxi1 [19] are indicated. The location of the Sin3 interaction domain (SID) in both exon 0– and exon 1–encoded
sequences is shown as an open star. Exon 1 and partial exon 0 aa sequences are indicated below mMxi1-1 and above mMxi1-0, respectively, with residues common
to both underlined. Common exon 2 sequence follows vertical bars in these sequences. The crosshatched dashed rectangle upstream of ATG in mMxi1-0 indi-
cates extent of novel sequence encoded by exon 0. Ovals indicate the location of sequence encoded by disrupted exon 2 in themxi1 knockout [26]. (B) Comparison of
human and mouse exon 0 nucleotide sequences. Significant homology is observed between human (GenBank Accession No. AL360182) and mouse (GenBank
Accession No. NT_039692) sequences, with differences indicated by hatched rectangles. The shaded rectangle indicates the location of the cytosine residue that
was absent from the Shimizu et al. [31] mMxi1-0 sequence, the presence of which permits an open reading frame fromATG #0 (underlined). Originally defined ATG#1
start codon frommMxi1-0 is also underlined. (C) Comparison of human andmouse exon 0–encoded amino acid sequences. Again, significant homology is observed,
with differences indicated by rectangles. Sequence common to that predicted by Shimizu et al. [31] is underlined, with initial methionine indicated by arrow.
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Like hMxi1, this mMxi1 isoform was able to repress tran-
scription (SR, strong repressor) and antagonize c-Myc–
dependent transformation. Of note, this group described a
second mouse Mxi1 variant with distinct transcriptional re-
pressive abilities—the so-called weak repressor (WR)—that
differed only in the absence of the exon 1–encoded SID. The
presence of a cryptic ATG in exon 2 of mouse mxi1 could
account for the absence of the SID in the WR isoform. At the
same time, Shimizu et al. [31] identified an alternative mouse
Mxi1 isoform (subsequently referred to here asmMxi1-0) that
was identical to mMxi1-1 in its C terminus, but differed
substantially in its initial N-terminal amino acid sequence
(Figure 1A). No specific information related to the functional
activity of mMxi1-0 has been reported, and only a single
subsequent reference has been made to mMxi1-0 [32]. The
discrepancy between the two mouse mxi1 forms has not
been reconciled in the literature.
We have recently discovered hMxi1-0, an isoform of Mxi1
translated from an alternative transcript derived from a pro-
moter upstream of a previously unidentified exon (exon 0) at
both the human MXI1 and mouse mxi1 loci. hMxi1-0 shares
significant homology with mMxi1-0, indicating cross-species
conservation. Intriguingly, hMxi1-0 is expressed at relatively
higher levels in tumor cells compared with normal tissues.
Functional analysis of hMxi1-0 indicates that whereas it is
able to heterodimerize with Max and recruit Sin3, it lacks
the ability of Mxi1 to repress Myc-dependent transcription.
The recognition that the same locus yields protein products
with distinct activities represents a novel mechanism by
which the repressive activity of Mxi1 might be attenuated or
antagonized in the absence of somatic mutation within Mxi1
coding exons. This finding has implications for regulation of
the activity of other Myc/Mad family members and also for
the published phenotype of the mxi1 knockout mouse.
Materials and Methods
Plasmid Construction
MXI1-0 and MXI1 cDNAs were amplified from a human
heart cDNA library (BD Biosciences-Clontech, Palo Alto, CA)
using BamH1 sequence containing forward primers (5V-CG-
GGATCCCATGGGCAAACGCGGGCGG-3V and 5V-CGCG-
GATCCTCTAGACCATGGAGC GGGTGAAGATGATC-3V,
respectively), and a reverse primer (5V-CGCGGATCCTTA-
AGCGT AGTCTGGGACGTCGTATGGGTACAAGCTT-
GAAGTGAATGAAAGTTTGAC-3V) that includes coding
sequence for an influenza hemagglutinin (HA) peptide epi-
tope (YPYDVPDYA). This HA tag permits detection of
either Mxi1-0-HA or Mxi1-HA using anti –HA antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, and Roche,
Indianapolis, IN). TheMXI1-0-HA andMXI1-HA cDNAs were
subcloned into the following: 1) the pcDNA3.1 eukaryotic
expression vector (Invitrogen, Carlsbad, CA); 2) the pIRES2-
EGFP eukaryotic expression vector (BD Biosciences-
Clontech); and 3) the pET-30a(+)vector (Novagen, San
Diego, CA) for preparation of purified 6xHistidine-tagged
protein in bacteria. DNA fragments corresponding to se-
quences unique to exon 0 and exon 1 were also subcloned
into pBluescript KS (Stratagene, La Jolla, CA) to permit
generation of exon 0– and exon 1–specific RNA probes.
An XhoI/NcoI DNA fragment containing 1000 bp of genomic
sequence upstream of the MXI1-0 ATG#0 was cloned into
the pGL3-Basic luciferase vector (Promega, Madison, WI) in
both forward (pGL3Basic-Ex0P) and reverse (pGL3Basic-
Ex0PRev) orientations for transcription studies. Similar
constructs containing 435 and 145 bp were prepared
using ApaL1/NcoI and PstI/NcoI fragments, respectively.
The pGLDH637Luc luciferase reporter (a Myc-responsive,
E-box-containing LDH promoter-luciferase reporter plasmid
[33]) and pRSV-Myc expression plasmids were a gift of C.
Dang (Baltimore, MD). pCMV-Max-YFP-FLAG was a gift of
Tom Kerppola (Ann Arbor, MI), and pCS2+MT-mSin3A was
a gift of Don Ayer (Salt Lake City, UT). DNA sequencing was
performed to confirm appropriate sequence and orientation
of each plasmid vector. Sequencing was performed using
the fluorescent dideoxy terminator method of cycle se-
quencing on a PE/ABd 373a automated DNA sequencer
following ABd protocols at the University of Michigan DNA
Sequencing Core.
Cell Culture
U87MG and U373MG glioblastoma cells (ATCC, Mana-
ssas, VA) were maintained in Eagle’s minimum essential
medium (EMEM) supplemented with 10% FBS, penicillin/
streptomycin and L-glutamine. K562 cells were passaged in
RPMI 1640 with 10% FBS with additives. NIH3T3 fibroblasts
and COS7 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% FBS with additives.
Restriction Landmark Genome Scanning
Restriction landmark genome scanning [34–36] was per-
formed using IMR-32 human neuroblastoma cells as de-
scribed previously [37,38].
Genome Analysis
A P1 clone derived from human chromosome 10 and
including the MXI1 locus was obtained from Genome Sys-
tems Inc. (St. Louis, MO) after screening with MXI1-0– and
MXI1-specific primer pairs. Southern blot analysis was per-
formed with digoxigenin-labeled probes (Roche) after restric-
tion digestion with multiple enzymes according to standard
protocols. Chromatograms of sequences were analyzed both
visually and using MacVector 6.5.3 with AssemblyLIGN
(Accelrys, San Diego, CA). A BLAST search identified a hu-
man chromosome 10 genomic sequence that included exon 0
(GenBank Accession No. AL360182), and each of the MXI1
exons 0 to 6 was matched up with this sequence using
MacVector to identify interexon distances. Similarly, mouse
chromosome19genomicsequence (GenBankAccessionNo.
NT_039692) was also found to containmxi1 exons 0 to 6.
Luciferase Assays
To evaluate transcription through the MXI1-0 promoter,
transfections were performed as previously described [39]
in hematopoietic K562 cells, as well as U87MG and U373MG
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glioblastoma cell lines. K562 cells growing in log phase
were washed with ice-cold Opti-MEM (Invitrogen) and re-
suspended in Opti-MEM at a concentration of 5  107/ml.
A total of 1  107 cells were incubated with 5 mg of
pGL3Basic-Ex0P, pGL3Basic-Ex0PRev, or pGL3-Basic-
Ex1P promoter luciferase plasmids and 50 ng of pRL-TK
Renilla vector (Promega) at room temperature for 10
minutes. Cells were transfected by electroporation with a
BTX Electro Cell Manipulator 600 at 350 V, 650 mF, and 13
V. Cells were then incubated at room temperature for 15
minutes and transferred to 3 ml of prewarmed (37jC) RPMI
1640 medium with additives. The transfected cells were
maintained in 5% CO2 at 37jC for 18 h, at which time they
were harvested, and both luciferase and Renilla activity were
measured on a Monolight 3010 luminometer (BD Bioscien-
ces Pharmingen, San Diego, CA) using the Dual-Luciferase
assay system (Promega). Luciferase (L) activity values were
normalized to the Renilla (R) activities for each sample (L/R),
and reported relative to pGL3-Basic-MXI1 (100%). All reac-
tions were performed in triplicate and repeated at least three
times; results are expressed as the mean ± SEM. U87MG
and U373MG cells were electroporated at 175 V, 850 mF, and
72 V, transferred to EMEM, and subsequently treated as
described for K562 cells.
Northern Blot Analysis
Single-stranded RNA probes specific to MXI1-0 and
MXI1 were generated by reverse transcription from pBlue-
script plasmids containing either exon 0 or exon 1, and end-
labeled with 33P. Premade multiple tissue fetal and adult
Northern blots (Invitrogen) were probed according to the
manufacturer’s instructions. Autoradiographs were obtained
at 48 hours.
Multiplex RT-PCR Assay
An MXI1/MXI1-0–specific multiplex, one-step reverse
transcription–polymerase chain reaction (RT-PCR) assay
(Access RT-PCR, Promega) was set up using separate
forward primers for exon 0 (5V-GACATTTTCAACACCAGC-
GAGAA CTCGATG-3V) and exon 1 (5V-CAACGTGCAGCG-
TCTGCTGGAGGC-3V) and a common reverse primer
from exon 3 (5V-CGATTCTTTTCCAGCTCATTGTG-3V)
(Figure 4B). Two hundred nanograms of total RNA was
used for the template. Reverse transcription was performed
for 45 minutes at 48jC, followed by 35 cycles of: denatur-
ation (94jC for 30 seconds), annealing (58jC for 1 minute),
and extension (68jC for 2 minutes), with a final 7-minute,
68jC extension. A Perkin-Elmer GeneAmp PCR System
2400 was used for amplification. The expected product sizes
for MXI1-0 and Mxi1 are 281 and 216 bp, respectively.
Quantitation of band intensity was performed using KODAK
1D Image Analysis Software (Rochester, NY).
Immunofluorescence
COS7 cells were transiently transfected with pIRES2-
EGFP-MXI1-HA or pIRES2-EGFP-MXI1-0-HA using
FuGENE 6 (Roche). Forty-eight hours later, cells were
permeabilized with 0.02% saponin in Buffer A (150 mM
KCl, 2 mM MgCl2, 20 mM HEPES, 1 mM EGTA, 1 mM
EDTA, 10% glycerol) for 15 minutes at 4jC, fixed with 100%
methanol for 5 minutes at 20jC, and then stained with
1:200 primary rabbit anti–HA antibody (Roche) followed by
Cy3-conjugated 1:400 secondary goat anti–rabbit antibody
(Jackson ImmunoResearch Laboratories, West Grove, PA).
Cells were visualized with a CoolSnap Pro CCD camera
(Media Cybernetics, Carlsbad, CA) on a Nikon Eclipse E600
microscope or a Zeiss LSM510 confocal microscope.
In Vitro Transcription/Translation and Western Blot Analysis
pcDNA3.1-MXI1-0-HA or pcDNA3.1-MXI1-HA plasmids
were used in the TNT T7 Quick Coupled Transcription/
Translation System (Promega) according to the manufactur-
er’s instructions. 35S-methionine labeling and Western blot
analysis were used for protein detection. For Western blots,
cell lysates were subjected to three freeze-thaw cycles,
sonicated, normalized for total protein concentration, mixed
with equal volumes of 2  loading buffer, and boiled for
10 minutes at 95jC. Samples were separated on a 12%
acrylamide SDS gel, followed by transfer to a polyvinylidene
fluoride (PVDF) membrane (Bio-Rad, Hercules, CA). HA-
tagged proteins were detected with a rabbit polyclonal anti–
HA antibody (Santa Cruz Biotechnology), followed by goat
anti–rabbit IgG HRP (Jackson ImmunoResearch Laborato-
ries). An HA-tagged Bcl-xS protein (gift of G. Nunez) was
used as a positive control for the HA antibody, and an
expected band of approximately 22 kDa was observed (data
not shown). FLAG-tagged Max was detected with either
mouse anti–FLAG antibody (Sigma, St. Louis, MO) or
mouse anti-Max antibody (Santa Cruz Biotechnology), and
Myc-tagged mSin3A was detected with rabbit anti–c-Myc
antibody (Santa Cruz Biotechnology). The enhanced chemi-
luminescence system (Amersham-Pharmacia, Buckingham-
shire, UK) was used for detection according to the
manufacturer’s instructions.
Coimmunoprecipitation
COS7 cells were plated in six-well plates at a density of
1.5  105 cells/well. Plated cells were transfected with 1 mg
of pIRES2-EGFP-MXI1-HA, pIRES2-EGFP-MXI1-0-HA, or
‘‘empty’’ pIRES2-EGFP and 1 mg of pCS2+MT-mSin3A,
using FuGENE 6 at a ratio of 3:1 FuGENE 6 to DNA.
Twenty-four hours after transfection, cells were washed with
1  PBS. Cells were lysed with 275 ml immunoprecipitation
(IP) lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1%
NP40, with Complete Mini Protease Inhibitor Cocktail
(Roche)) and transferred to cold 1.5-ml microcentrifuge
tubes. Lysates were sonicated and centrifuged at >10,000g
for 10 minutes at 4jC to separate insoluble proteins. The
supernatant was transferred to ice-cold tubes and an aliquot
was saved as whole cell lysate (WCL). Protein lysates were
incubated with 1 mg of immunoprecipitation antibody (anti-HA
or anti-Myc for Mxi-Sin3, and anti-HA or anti-FLAG for Mxi-
Max) at 4jC rotating for 1 hour. Fifty microliters of protein
A/G (1:1) Sepharose (Zymed Laboratories, San Francisco,
CA) was added to each reaction and the mixture incubated
an additional 2 hours. Immune complexes were pelleted by
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centrifugation at 4000 rpm (4jC) and washed four times with
IP wash buffer (PBS + 100 mM KCl and 0.25% NP40) before
SDS-PAGE and Western blot analysis.
Electrophoretic Mobility Shift Assays
A double-stranded oligonucleotide probe containing the
CACGTG Myc/Max binding site was synthesized by heating
a pair of complementary oligonucleotide primers (5V-CCCG-
ACC ACGTGGTCTGA-3V and 5V-TCAGACCACGTGGTC-
GGG-3V) to 95jC for 10 minutes and then cooling slowly to
room temperature. After hybridization, probes were end-
labeled with 32P. Purified Max, MXI1-0, and Mxi1 proteins
were prepared from pET-30a(+)-Max, –Mxi1-0, or –Mxi1
transformed BL21(DE3) E. coli bacteria (Stratagene) using
previously described methods [40]. DNA–protein reactions
were performed in gel mobility shift buffer (10 mM Tris–HCl
(pH 7.4), 80 mM NaCl, 1 mM dithiothreitol, and 5% glycerol),
with purified Max and MXI1-0 or Mxi1 proteins, 0.25 mg of
herring sperm DNA, and 0.5 mg of poly(dI-dC). Reactions
were incubated at 42jC for 15 minutes and at 20jC for 15
minutes after adding 32P-labeled probe. Where indicated,
anti-Max antibody (Santa Cruz Biotechnology) was then
added, and incubation was continued at room temperature
for 15 minutes. The DNA–protein complexes were analyzed
on a 5% polyacrylamide gel run at 16jC in 0.25  TBE
buffer at 200 V for 2 hours.
Transcription Assays
To assess the effect of MXI1-0 and Mxi1 on c-Myc–
dependent transcription, 1.2  105 NIH3T3 fibroblasts were
cotransfected with 1 mg of pGLDH637Luc (a Myc-respon-
sive, E-box-containing LDH promoter– luciferase reporter
plasmid [33]), 100 ng of pRSVMyc (a eukaryotic expression
plasmid that constitutively expresses c-Myc under control of
the RSV promoter), and 500 ng of either pIRES2-EGFP-
MXI1-0-HA, pIRES2-EGFP-MXI1-HA, or pIRES2-EGFP.
Transfections were performed with FuGENE 6, and luci-
ferase assays (Promega) were performed 24 hours after
transfection. Initial studies were performed with the Dual-
Luciferase assay system, but the presence of even small
amounts of Renilla luciferase plasmid reduced the baseline
firefly luciferase levels, so subsequent transfections were
normalized for total protein by the Bradford method. Reac-
tions were performed in triplicate and repeated at least three
times; results are expressed as the mean ± SEM.
Tumor and Normal Brain Specimens
RNA was prepared using an RNeasy Kit (Qiagen, Valen-
cia, CA) from frozen specimens obtained from 10 patients
with histologically confirmed glioblastoma multiforme, as well
as seven normal brain samples obtained from patients who
underwent biopsy for nonmalignant conditions. Specimens
had been obtained, coded (patient-specific identifiers were
stripped), and frozen in liquid nitrogen as part of a University
of Michigan human brain tumor bank >5 years previously;
there was no possibility to link specimens to individual
patients. Approval to analyze specimens was obtained from
the University of Michigan Institutional Review Board.
Results
Identification of MXI1-0, a Novel Mxi1 Isoform, in Human
Neuroblastoma
We used the technique of restriction landmark genome
scanning [34–36] to perform an unbiased search for
expressed genes that are upregulated in the IMR-32 human
neuroblastoma cell line [37,38]. A spot on a 2-D gel that was
significantly upregulated in these cells was extracted,
cloned, and sequenced, and found to be identical to human
MXI1 (hMXI1) in its 3V end, but lost homology at the junc-
tion of the first and second exons of hMXI1 (Figure 1A,
hMxi1-0). Surprisingly, the sequence of the 5V end of this
cDNA was identical to the 5V sequence of mMxi1-0, but
included 183 additional base pairs of upstream sequence
that was similar to available sequence from the 5V ‘‘untrans-
lated’’ region of mMxi1-0. The human and mouse upstream
sequences were 92% (169/183) identical at the nucleotide
level (Figure 1B), but the hMXI1-0 sequence included an
additional single cytosine base pair in a polyC tract lo-
cated 80 bp upstream of the previously identified ATG. Of
note, the additional cytosine was present in both human
and mouse genomic sequences (Figure 1B), in contrast to
the originally described Shimizu et al. [31] 5V untranslated
mMxi1-0 sequence. This ‘‘frameshift’’ relative to mMxi1-0
allows for an in-frame upstream ATG start codon that, when
translated, encodes 61 additional N-terminal amino acids.
This proline-rich region includes consensus motifs for ami-
dation (aa 1–4), myristylation (aa 17–22), and glycosylation
(aa 56–59), but there are no other protein homology motifs
from the PROSITE database. Specifically, the region con-
tains no known nuclear localization or cytoplasmic retention
motifs. The identification of this novel sequence suggested
that it might be encoded by an alternative exon distinct from
exon 1. Thus, the novel isoform (dubbed ‘‘MXI1-0 ’’) shares
exons 2 to 6 with hMxi1, but differs from hMxi1 in having
an alternative first exon (exon 0 GenBank Accession No.
AY576484). Exon 0 aa 62 to 91 are similar (but not
identical) to exon 1 aa 1 to 25, and, like exon 1, encode a
predicted SID. The human and mouse exon 0 sequences
are 95% (259/274) similar at the DNA level (Figure 1B)
and the encoded amino acids are 93% (84/90) similar
(Figure 1C).
Localization of Exon 0 Upstream of Exon 1 on Human
Chromosome 10 and Mouse Chromosome 19
We obtained a human genomic bacterial artificial chromo-
some (BAC) clone that contains sequences present in both
exon 0 and exon 1, and mapping analysis (by Southern blot
after digestion with different restriction enzymes; data not
shown) indicated that exon 0 was approximately 20 kb
upstream of exon 1 (Figure 2). Subsequent analysis of hu-
man chromosome 10 genomic DNA sequence (GenBank Ac-
cession No. AL360182) identified theMXI1 exon 0 sequence
18,088 bp upstream of exon 1, confirming that this sequence
represents a distinct exon. Sequence analysis of mouse
chromosome 19 (GenBank Accession No. NT_039692) also
identified exon 0 approximately 18,996 bp upstream of
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exon 1 (Figure 2), and illustrates conservation of genomic
structure between the human MXI1 and mouse mxi1 loci.
Sequences Upstream of Exon 0 Contain a Putative
Promoter
If the exon 0 genomic sequence encodes a distinct
transcript, sequences upstream of the exon 0 ATG#0 (that
presumably regulate its transcription) should demonstrate
promoter activity in a luciferase assay. Because we have
previously characterized the MXI1 exon 1 promoter [39], we
tested the promoter activity of a luciferase construct con-
taining 1000 bp of putative human MXI1-0 promoter se-
quence upstream of the putative exon 0 start codon
(ATG#0 in Figure 1B). Parallel transfections with MXI1-0
and MXI1 promoter constructs showed similar levels of
promoter activity (Figure 3A) in both U87MG and U373MG
glioblastoma cells, and in K562 erythroleukemic cells, indi-
cating inherent MXI1-0 transcriptional activity in these cell
lines. Deletion analysis of putative MXI1-0 promoter con-
structs in K562 cells showed promoter activity within 435 bp
of sequence upstream of ATG#0, but no activity above
background with constructs that include either 145 bp up-
stream of ATG#0, or 328 bp (= 145 + 183 bp) upstream of
ATG#1 (Figure 3B). Thus, promoter studies are consistent
with the notion that MXI1-0 is a novel protein whose expres-
sion is subject to specific regulation, and suggest that the
183 bp corresponding to the MXI1-01–61 amino terminal
extension is encoded.
Expression of MXI1-0 and MXI1
Northern blot analysis with exon-specific probes was
used to compare relative levels of MXI1-0 and MXI1 expres-
sion in different human tissue types. In contrast to MXI1,
MXI1-0mRNA is expressed more prominently in human fetal
tissue (Figure 4A). Conversely, MXI1 is expressed at higher
levels in adult human tissues (data not shown).
To analyze relative levels of MXI1-0 and MXI1 expres-
sion, we developed a multiplex RT-PCR assay, using exon
0– and exon 1–specific forward primers and a common
reverse primer in exon 3 (Figure 4B). Although the RT-PCR
technique is inherently semiquantitative, the use of a com-
mon reverse primer, together with the similar product size,
permits direct comparison ofMXI1-0 andMXI1 expression in
a given cell or tissue type. Specifically, measuring the ratio of
MXI1-0/MXI1 band intensities provides a semiquantitative
indication of relative transcript levels within a given sample,
and this ratio may be compared between samples. We have
detected both MXI1-0 andMXI1 transcripts by PCR in cDNA
libraries derived from both human and mouse tissues (Figure
4C), indicating that both isoforms are coexpressed.
Finally, we determined the intracellular localization pat-
terns of MXI1-0 and Mxi1. As we [24] and others [41] have
observed previously, overexpression of Mxi1 in COS7 cells
results in a speckled nuclear expression pattern (Figure 5, a
and b). In contrast, MXI1-0 appears predominantly in the
cytoplasm, with only minimal expression in the nucleus
(Figure 5, c and d ). Similar patterns were observed in
U87MG glioblastoma cells (data not shown). Thus, in spite
Figure 2. (A) Genomic organization of human and mouse MXI. Exon 0 lies approximately 19 kb upstream of exon 1. MXI1 mRNA is transcribed from a promoter
immediately upstream of exon 1 (filled arrow), whereas MXI1-0 mRNA transcription initiates upstream of exon 0 (open arrow), with splicing out of exon 1. Exons are
indicated by shaded ovals, and distances between exons are shown in base pairs. Genomic organization is based on GenBank sequences for human chromosome
10 (GenBank Accession No. AL360182) and mouse chromosome 19 (GenBank Accession No. NT_039692). The actual size of mouse intron 3 is almost certainly
greater than indicated here, because the available GenBank sequence contains several N stretches. (B) Derivation of MXI1-0 and MXI1 transcripts. Spliced introns
are indicated by diagonal lines. Note that exon 1 is spliced out of the MXI1-0 transcript.
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of their similarity, MXI1-0 and Mxi1 have strikingly different
intracellular localization patterns.
MXI1-0 Interacts With Sin3 and Dimerizes With Max to
Recognize E-Box Sequences
The predicted sizes of the translated MXI1-0 and Mxi1
proteins are 32 and 26 kDa, respectively. This was confirmed
by in vitro translation using plasmids encoding HA-tagged
MXI1-0 or Mxi1 (Figure 6A). We used immunoprecipitation to
demonstrate that MXI1-0, like Mxi1, is able to interact with
both Max (Figure 6B) and Sin3 (Figure 6C). Identical results
were obtained with Mxi1 or Sin3 IP pulldowns, indicating that
the N-terminal 60 amino acids present in MXI1-0 does not
affect interaction with Sin3 through the SID. Furthermore,
like Mxi1, MXI1-0 interacts with Max and binds to CACGTG-
containing DNA sequences in the electrophoretic mobility
shift assay (Figure 7). Thus, MXI1-0 interacts with Sin3 and
dimerizes with Max to recognize E-box sequences, indicat-
ing that it might have transcriptional regulatory activity.
MXI1-0 Lacks Significant Transcriptional Repression Activity
The discovery thatMXI1-0 expression is increased in fetal
tissues suggested that MXI1-0 might be associated with
proliferation, rather than growth suppression like Mxi1. Thus,
we have begun to study the functional activity of MXI1-0 in
comparison with Mxi1. We determined the effect of MXI1-0
on c-Myc–dependent transcription in a transient transfec-
tion assay with an LDH promoter reporter construct that
contains two E-box binding sites. Baseline transcription
activated by c-Myc was significantly reduced (by 50%) in
Figure 3. (A) Exon 0 promoter activity is detectable in different cell lines. Luciferase activity of pGL3Basic-Ex0P (p3BEx0) or pGL3BasicEx0PRev (p3BEx0Rev, the
1-kb exon 0 promoter fragment in reverse orientation) reporter constructs transfected into glioblastoma (U87MG, U373MG) or myeloid leukemia (K562) cells
are shown. Luciferase activities are shown relative to pGL3Basic-Ex1P (p3BEx1, 100%), and have been normalized to cotransfected Renilla activities. Each
experiment was performed in triplicate a minimum of three times, and error bars indicate standard error of the mean. (B) Deletion analysis of exon 0 promoter.
Portions of exon 0 promoter (100, 435, and 145 bp) cloned into pGL3Basic are indicated by solid black arrows, with exon 0 coding sequence shown as gray bars.
Positions of ATG#0 and ATG#1 are indicated, with 183 bp of intervening sequence. 145/+183 refers to pGL3Basic construct containing sequence upstream of
ATG#1. Relative promoter activity in K562 cells is indicated.
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the presence of Mxi1 in comparison with empty vector
(Figure 8). In contrast, MXI1-0 cotransfection did not signif-
icantly affect levels of Myc-dependent transcription. Neither
MXI1-0 nor Mxi1 affected E-box–dependent transcription in
the absence of c-Myc (data not shown). These results
indicate that MXI1-0 is unable to repress c-Myc–dependent
transcription.
MXI1-0 Is Overexpressed Relative to MXI1 in Glioblastoma
Tumors
Because MXI1-0 does not repress c-Myc–dependent
transcription, its coexpression with Mxi1 could antagonize
Mxi1-dependent growth suppression. We therefore hypoth-
esized that MXI1-0 might be overexpressed relative to Mxi1
in tumor cells as compared with normal tissue. We used the
multiplex RT-PCR assay to evaluateMXI1-0 andMXI1 levels
in primary human glioblastoma tumors compared with nor-
mal brain tissue. We found that the MXI1-0/MXI1 ratio is
elevated in 10 of 10 primary glioblastoma tumors, as com-
pared with normal brain specimens (Figure 9), and also in
three glioblastoma tumor cell lines (data not shown). Thus,
these studies indicate that MXI1-0 mRNA transcripts are
overexpressed relative to MXI1 in glioblastoma tumors as
compared with normal brain tissue.
Discussion
After the original discovery of human MXI1 [6], two groups
independently described a mouse mxi1 homolog [19,31].
The amino acid sequence of one form (mMxi1) [19] was
essentially identical to human Mxi1 with the exception of
minor changes in the C-terminal region (Figure 1). An al-
ternative mouse Mxi1 isoform (referred to here as mMxi1-0
[31]) was identical to mMxi1 in its C terminus, but differed
substantially in its N-terminal amino acids (Figure 1). Only a
single subsequent reference has been made to mMxi1-0
[32]. No specific information related to the functional activity
of mMxi1-0 has been reported, and the discrepancy between
the two mouse mxi1 forms has not been addressed in the
literature. In a search for genes that are upregulated in
Figure 4. MXI1-0 and MXI1 expression patterns. (A) MXI1-0 mRNA is preferentially expressed in fetal tissues. REAL Hu Fetal mRNA blots 1 and 2 (BD
BioSciences-Clontech) were probed with cRNA probes specific for exon 0 (top panel) or exon 1 (bottom panel). Blots were probed with exon 1 probe first, stripped,
then reprobed with exon 0 probe. The expected size of MXI1 mRNA is 2.8 to 3.0 kb (based on previous reports) [6,55] and MXI1-0 mRNA signal is comparable in
size. (B) Schematic of multiplex RT-PCR. Solid black bar indicates exon 0, white bar is exon 1, diagonal black striped bar is exon 2, gray bar is exon 3, and dotted
bar is exon 4. Forward primers specific for exon 0 (Ex0-F) and exon 1 (Ex1-F) and a common reverse primer from exon 3 (Ex3-R) are used to amplify 281- and
216-bp products, respectively. (C) MXI1-0 and MXI1 are both expressed in both human and mouse cDNA. PCR was performed with MXI1-0– and MXI1-specific
forward primers and a common reverse primer, using human heart (H) or mouse pGAB (M) cDNA libraries (gift of G. Nunez). Both MXI1-0 and MXI1 bands are
amplified from each cDNA source.
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human neuroblastoma we have identified human MXI1-0,
and in this report we begin to characterize this alternatively
transcribed Mxi1 isoform.
The human MXI1-0 isoform shares exons 2 to 6 with
Mxi1, but differs from Mxi1 in having an alternative first exon
(exon 0). Like exon 1, exon 0 encodes a Sin3 interaction
domain (aa 62–92); however, exon 0 also encodes 61
additional N-terminal amino acids. Whereas this proline-rich
region includes consensus motifs for amidation, myristyl-
ation, and glycosylation, there are no other protein homology
motifs (responsible for either nuclear localization or cyto-
plasmic retention) from the PROSITE database. The ab-
sence of exon 0 sequence from the intron between hMXI1
exons 1 and 2 [17] suggested that it was derived from an
additional, more upstream, alternative first exon (exon 0)
(Figure 2), and examination of both human and mouse
GenBank genomic sequences revealed the presence of
exon 0 18 to 19 kb upstream of exon 1. Because we have
only observed exon 0 juxtaposed to exon 2—and never to
exon 1—transcription through the exon 0 promoter must
result in the splicing out of exon 1. Exon 0 therefore repre-
sents an alternative first exon.
The splicing of alternative first exons to a common set of
downstream exons represents a mechanism by which di-
verse RNAs (and ultimately proteins) can be generated. It
has recently been estimated that a large number of human
genes (>3000) contain multiple variable first exons [42].
Although most of these genes (f80%) have two alternative
first exons, as many as 10 variable first exons have been
identified for some genes. Proteins encoded by variable
transcripts have been shown to have differences in function
[42], different subcellular localization patterns [43], promoter-
dependent differential tissue or lineage expression [42],
altered posttranscriptional gene regulation through mRNA
processing, export, stability, or altered translation potential
[44], or modified ‘‘native’’ protein function, resulting in a
dominant negative phenotype [45,46]. Although alternative
transcripts (derived from distinct promoters or splicing path-
ways) that encode proteins with distinct functions have been
reported for many proliferation-related genes (including c-
Myc and Myb [47,48]), our identification of MXI1-0 repre-
sents the first Mad family member derived from an alterna-
tive transcript. The presence of an alternative first MXI1
coding exon raises the possibility that other MAD family
genes might also harbor alternative first exons. Although
sequences homologous to MXI1 exon 0 are not found
upstream of the human MAD1, MAD3, and MAD4 genes,
these genes might include other alternative upstream exons.
It is possible, however, that the alternative MXI1-0 transcript
is unique to the MXI1 locus. Because MXI1 is the only MAD
family gene to date whose inactivation is associated with a
tumorigenic phenotype [49,50], the expression of MXI1-0
may be required for tight regulation of Mxi1 expression.
Our identification of MXI1-0 reveals an additional, previ-
ously unappreciated level of complexity to regulation within
the Myc/Max network and prompts speculation about the
Figure 5. Intracellular localization of Mxi1 and MXI1-0. COS7 cells were transiently transfected with pIRES2-EGFP-MXI1-HA (a, b) or pIRES2-EGFP-MXI1-0-HA
(c, d), permeabilized, fixed, and then stained with primary rabbit anti –HA antibody followed by Cy3-conjugated secondary goat anti – rabbit antibody. Images
shown were taken with wide-field epifluorescence microscopy (A, C, original magnification,  200) or confocal microscopy (b, d, original magnification, 500).
Note primarily punctuate nuclear distribution of Mxi1, and diffuse cytoplasmic (nonnuclear) expression pattern of MXI1-0.
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possible function of MXI1-0. The ability of MXI1-0 to interact
with Max and with DNA (Figures 6B and 7) is not surprising,
given the fact that MXI1-0 and Mxi1 share identical DNA
binding and HLH-ZIP domains. The interaction with Sin3 is
also expected because the 3V portion of exon 0 encodes a
SID similar to that of Mxi1 and other Mad family members.
On this basis, MXI1-0 would be predicted to synergize with
Mxi1 and inhibit Myc activity, and so it is surprising thatMXI1-
0 is unable to inhibit Myc-dependent transcription (Figure 8).
It is notable, however, that the intracellular expression pat-
tern ofMXI1-0 differs remarkably from that of Mxi1. Whereas
Mxi1 exhibits a predominantly speckled nuclear pattern,
Figure 6. MXI1-0 and Mxi1 protein interactions. (A) Expression of MXI1-0 and Mxi1 proteins. 35S-labeled reticulocyte lysate in vitro transcription/translation of HA-
tagged MXI1-0 and Mxi1 demonstrates translated proteins with the expected size difference. (B) MXI1-0 and Mxi1 both interact with Max. COS7 cells were
transiently transfected with pCMV-Max-YFP-FLAG (lanes 1–9), and pIRES2-EGFP expression vectors for MXI1-0-HA (lanes 1, 4, and 7), Mxi1-HA (lanes 2, 5,
and 8) or empty vector (lanes 3, 6, and 9). Immunoprecipitation (IP) was performed with anti –HA or anti –FLAG antibodies, and after electrophoresis, blots were
probed with either anti –HA or anti –Max antibodies. Whole cell lysates (WCLs) that were not subjected to IP (lanes 7–9) contained the expected proteins upon
Western blotting. (C) MXI1-0 and Mxi1 both interact with Sin3. COS7 cells were transiently transfected with a myc-tagged mSin3A expression vector (pCS2+MT-
mSin3A, lanes 1–9), and pIRES2-EGFP expression vectors for Mxi1-0-HA (lanes 1, 4, and 7), Mxi1-HA (lanes 2, 5, and 8) or empty vector (lanes 3, 6, and 9).
Immunoprecipitation was performed with anti –HA or anti –Myc antibodies, and following electrophoresis, blots were probed with either anti –HA or anti –Myc
antibodies. WCLs that were not subjected to IP (lanes 7–9) contained the expected proteins upon Western blotting.
MXI1-0 Is Overexpressed in Glioblastomas Engstrom et al. 669
Neoplasia . Vol. 6, No. 5, 2004
MXI1-0 is primarily localized to the cytoplasm (Figure 5).
Because MXI1-0 and Mxi1 differ only in their amino termini,
the cytoplasmic localization of MXI1-0 must be mediated by
amino acids in domains encoded by exon 0, most likely within
the 61 amino acid N-terminal extension. As a result, even
though MXI1-0 can bind to Sin3 (and potentially mediate
histone deacetylase recruitment, chromatin condensation,
and transcriptional repression), its predominantly cytoplas-
mic localization may preclude a transcriptional regulatory
role in the nucleus, resulting in the inability of MXI1-0 to
repress Myc-dependent transcription.
Alternatively, because MXI1-0 includes domains for Sin3
interaction, Max dimerization and DNA binding, it is tempting
to speculate that MXI1-0 may regulate transcription under
Figure 7. Mxi1-0-Max and Mxi1-Max both recognize and bind to E-box-containing DNA. Purified 6xHis-Max without (lanes a and c) or with 6xHis-Mxi1 (lanes d
and f) or 6xHis-Mxi1-0 (lanes e and g) proteins were mixed together and incubated for 15 minutes at 42jC. A 32P-labeled E-box–containing oligonucleotide probe
was added and incubated for 15 minutes at RT. Where indicated, anti-Max antibody was added and incubated for an additional 15 minutes at RT (lanes b, f, and g).
The positions of shifted and supershifted band complexes are shown; Max2 denotes the position of Max–Max homodimers bound to DNA, and ** indicates a less
prominent subshifted band seen only with purified Max.
Figure 8. MXI1-0 fails to repress Myc-dependent transcription. NIH3T3 cells were cotransfected with an E-box-containing LDH– luciferase reporter plasmid (1 g),
pMLV c-Myc (0.1 g), and 0.5 g of empty pIRES2-EGFP vector (control), pIRES2-EGFP-Mxi1 (Mxi1), or pIRES2-EGFP-Mxi1-0 (MXI1-0). Lysates were prepared
after 24 hours; luciferase activity was quantified. The results are standardized to pIG empty control and expressed as the mean (± SEM) of 12 independent
experiments in triplicate.
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appropriate circumstances. It is possible that interaction
of MXI1-0 with an as yet undefined cytoplasmic protein
prevents MXI1-0 from appearing in the nucleus. Altered
interaction of MXI1-0 with this putative cytoplasmic protein
(as a result of posttranslational modification, e.g., phos-
phorylation) could then result in translocation of MXI1-0
to the nucleus with consequent transcriptional repression.
This phenomenon has recently been identified for p53 trans-
location to the nucleus in the context of Parc, a novel
cytoplasmic protein [51,52]. Movement of MXI1-0 from the
cytoplasm to the nucleus could therefore quickly and specif-
ically affect Myc transcriptional activity. This possibility is
currently being investigated.
At the same time, however, it is also possible thatMXI1-0
antagonizes Mxi1 activity, precisely because of its cytoplas-
mic localization. MXI1-0 could compete with Mxi1 for both
Max and Sin3, reducing the availability of Max for dimeriza-
tion and DNA binding and preventing Sin3-dependent tran-
scriptional repression. Cytoplasmic sequestration of Max
and/or Sin3 could make these proteins unavailable for inter-
action in the nucleus with other Myc or Mad family members.
Thus, a rapid increase in the relative amount of cytoplasmic
MXI1-0 could abrogate Mxi1 transcriptional repression in
dominant negative fashion. This would result in decreased
antagonism of Myc function by Mxi1, with a consequent
tendency to increased proliferation. It should be noted that
other Mxi1 isoforms (e.g., the WR form that lacks a SID [19],
or splice variants that are missing exon 3 [53]) could poten-
tially display similar antagonistic effects.
The MXI1 locus gives rise to distinct mRNA transcripts
encoding proteins that appear to have distinct biological
activities. In addition, the expression pattern of MXI1-0 is
distinct from that of MXI1: whereas mRNAs encoding both
isoforms are present in both human and mouse tissues and
cell lines, MXI1-0 is expressed more prominently than MXI1
in human fetal tissues (Figure 4) and in primary glioblastoma
tumors (Figure 9). This differential expression results, at
least in part, from a distinct, exon 0–specific promoter. Like
the previously characterized MXI1 promoter region [39],
putative MXI1-0 promoter sequences are active in both glial
and hematopoietic cell lines (Figure 3). These putativeMXI1-
0 regulatory sequences also contain consensus AP2 binding
sites, and preliminary experiments indicate that AP2-depen-
dent regulation of expression through the MXI1-0 promoter
is different from that of MXI1 (unpublished observations).
Based on these observations, we therefore hypothesize that
coexpression of MXI1-0 with Mxi1 modulates the suppres-
sive activity of Mxi1. Depending on the specific circumstan-
ces, MXI1-0 expression may contribute to increased cell
proliferation in both ‘‘immature’’ and neoplastic cells. Thus,
a relative increase in the MXI1-0/Mxi1 ratio represents a
previously unappreciated mechanism by which Mxi1 growth
suppression might be modulated.
The localization of the MXI1 gene to chromosome
10q24–q25, a glioblastoma hotspot, initially suggested that
MXI1 was a candidate tumor suppressor gene in glioblasto-
mas. Although we had previously identified MXI1 allelic loss
in a significant fraction of glioblastoma tumors [23], we and
others [25,54] have been unable to identify mutations in any
of the six known coding MXI1 exons in glioblastoma tumor
specimens. Interestingly, MXI1 coding sequence mutations
have been identified in several neurofibrosarcoma patients
[28]. Furthermore, we were unable to demonstrate methyl-
ation of the MXI1 promoter as a potential mechanism for
silencing the remaining MXI1 allele (manuscript in prepara-
tion). The identification of MXI1-0 suggests an alternative
means by which Mxi1 growth suppressive activity might be
downregulated. We have shown that MXI1-0 is overex-
pressed relative to MXI1 in 10 of 10 glioblastoma tumors,
whereasMXI1-0 andMXI1 levels are comparable in 7 normal
brain specimens (Figure 9). The consistent observation of
relatively increased MXI1-0 expression in glioblastoma tu-
mor specimens (but not normal brain) raises the intriguing
possibility that the presence of MXI1-0 counteracts the
suppressive activity of Mxi1.
The expression of the alternatively transcribed MXI1-0
isoform raises questions about the interpretation of previous
studies that measured MXI1 mRNA levels by Northern blot/
RT-PCR/in situ hybridization using probes or primers down-
stream of exon 1 (e.g., Refs. [6,55–59]). Whereas ectopic
expression experiments have clearly indicated a growth-
suppressive role for Mxi1 [23–25], studies examining endo-
genousMXI1 levels would have necessarily measured levels
of both MXI1 and MXI1-0. Since we have demonstrated
Figure 9. MXI1-0 is overexpressed in glioblastoma tumors. Semiquantitative multiplex RT-PCR and standard RT-PCR with GAPDH-specific primers was
performed with RNA from 7 normal brain specimens and 10 glioblastoma multiforme tumors. The numbers above the ethidium bromide–stained gel indicate the
ratio of MXI1-0 to MXI1 band intensity (normalized to GAPDH), with mean MXI1-0/MXI1 (Ex 0/Ex 1) ratio as indicated.
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substantial levels of both transcripts in a variety of different
cell lines, studies that have previously detailedMXI1 expres-
sion patterns now demand reexamination. To begin to ad-
dress this issue, we have observed that when U937 cells are
induced to differentiate with 12-O-tetradecanoylphorbol-13-
acetate (TPA) [55], levels of MXI1-0 and MXI1 expression
exhibit divergent patterns (unpublished observations).
Furthermore, the identification ofMXI1-0 has implications
for the phenotype of the published mxi1 knockout mouse
[26]. In this work, the targeting construct was prepared by
disrupting mxi1 exon 2. Because this exon is shared by both
Mxi1 andMXI1-0, the knockout mouse would be expected to
be deficient in both isoforms. If MXI1-0 antagonizes Mxi1,
then the effect of inactivating the growth (and potentially
tumor) suppressive activity of Mxi1 might be blunted in the
‘‘dual’’ knockout. Thus, it is possible that targeted inactivation
of only exon 1 might result in a more dramatic tumorigenic
phenotype, if MXI1-0 is still expressed. Studies are ongoing
to prepare an mxi1 exon 1–only knockout mouse.
In summary, we have identified an alternatively tran-
scribed isoform of the Mxi1 growth suppressor. MXI1-0,
transcribed from an alternative upstream exon, is similar to
Mxi1 in terms of its ability to interact with Max, Sin3, and E-
box–containing DNA. In contrast to Mxi1, MXI1-0 exhibits a
predominantly cytoplasmic expression pattern, fails to re-
press Myc-dependent transcription, and is expressed at
relatively higher levels in glioblastoma tumors. The identifi-
cation of MXI1-0 permits an additional level of regulatory
control over the activity of the Mxi1 growth suppressor and
deepens the complexity of gene regulation by the Mad
family. The existence of MXI1-0 has important implications
for previous studies describing both the expression and
functional inactivation of Mxi1.
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